The abstract is read at the publisher; the summary is JClub's.
X-Editor (XE), an engineered Cas12e-based CRISPR system, achieves more than 100-fold higher genome editing activity in human cells while maintaining exceptional specificity.
- Why it matters: Expanding CRISPR to more diseases requires stronger editing at low doses without increasing unintended genomic modification, especially under in vivo delivery constraints in large animals.
- What they did: The team iteratively engineered Cas12e and guide RNA by screening tens of thousands of variants and designs, using cryo-electron microscopy to identify interactions that enhance function.
- The result: In nonhuman primate liver, XE delivered as mRNA via lipid nanoparticle edits two targets at lower doses than comparable Cas9-based preclinical data, with no off-target editing detected in primary human hepatocytes at doses tenfold above EC90.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.